Biocare Medical Acquires Empire Genomics

Agilent Technologies Acquires Biocare Medical

March 9, 2026

Medical Devices

Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, for $950 million in an all-cash transaction. The acquisition expands Agilent’s pathology portfolio—particularly in immunohistochemistry (IHC)—and is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in Year 1.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

GHO Capital and Excellere Partners Invest in Biocare Medical

December 9, 2021

Medical Devices

London-based GHO Capital has invested in Biocare Medical, a California-headquartered developer of immunohistochemistry reagents and diagnostic instrumentation, alongside existing investor Excellere Partners. The capital will be used to accelerate R&D, expand the instrument offering, and support international expansion to capture growing demand for oncology diagnostics.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.